Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/303480483?client_source=feed&format=rss
sun flare love hewitt new ipad solar flare joseph kony 2012 arian foster dennis kucinich
Sunday, May 5, 2013
Saturday, May 4, 2013
Outgoing Alibaba CEO Ma says he's 'old' for Web
SANTA MONICA, Calif. (AP) ? Alibaba founder Jack Ma, the billionaire who has run the Chinese e-commerce giant since 1999, says he's getting "a bit old" for the Internet.
That's what the outgoing chief executive told a charitable event in Santa Monica Thursday as he pledged $5 million toward a China-based fund that supports environmental conservation projects outside China.
"I'm young for new things but I'm a bit old for the Internet," the 48-year-old said.
Ma's gift doubles the amount raised for the China Global Conservation Fund, an offshoot of the Arlington, Va.-based organization, The Nature Conservancy.
Ma steps down as CEO from Alibaba Group on May 10, ahead of a widely expected initial public offering of stock that could create a windfall for Yahoo Inc., which owns nearly a quarter of the company.
Ma said that he prepared for his retirement for the last nine years and is looking forward to working on philanthropic causes such as environmental conservation.
He said he was inspired to act after visiting his home in China six years ago. A lake he nearly drowned in as a boy had mostly dried up. He also spoke to a farmer who used chemicals on produce that he wouldn't feed his family. "I know something is wrong," Ma said.
Ma will chair the Chinese board overseeing the fund once he steps down as CEO.
Associated PressFriday, May 3, 2013
Survivor Caramoan Episode 12 Recap ? The Double Boot!
We have a busy Survivor Caramoan reap of Episode 12 which featured a double-boot with two Tribal Councils. So let us begin on Night 30 as the gang returns to Camp Enil Edam after booting Malcolm. Reynold and Eddie are running out of allies and options. Cochran is plotting to take over The Game, ready to make some ?big moves? when needed. Day 31 and tree-mail arrives announcing another Immunity Challenge. The former ?Stealth? alliance is already targeting Reynold to be their next victim. The IC event is an endurance one. Each player must stand on a triangular perch off shore. Every 15 minutes, the players will move up to the next level until the third which is just 4 inches wide. Not only are the perches floating, making them unstable, but there is also a strong breeze that is gusting, too. There is also a reward for the winner, a clue to the hidden immunity idol. Shortly after they begin, Jeff Probst offers a bribe of milk and donuts. Eddie and Erik bailout. After 15 minutes, the rest move up to the second level of the perches. Jeff offers another bribe, hotdogs and soda pop, which Cochran goes for. [...]
Source: http://feedproxy.google.com/~r/RightCelebrity/~3/CS2hlzmmKUw/
Espn Fantasy Football Grandparents Day 2012 army wives 60 minutes go daddy Tom Kenny Long Island Medium
Thursday, May 2, 2013
Taliban kill senior peace envoy in south Afghanistan
KANDAHAR, Afghanistan (Reuters) - Taliban fighters killed a senior member of Afghanistan's peace council on Wednesday, officials said, dealing another blow to nascent peace efforts with the insurgency.
President Hamid Karzai formed a 70-member High Peace Council in 2010 in a bid to reach a peace settlement with the insurgents, but little has been achieved, with the Taliban saying they will not talk with the Afghan government.
Malim Shahwali, the council's chief in the southern province of Helmand, was traveling to the violence-plagued Gereshk district when insurgents ambushed his convoy, said the provincial governor's spokesman, Omar Zwak.
"First an explosion hit his convoy and then the Taliban gunmen opened fire, killing Malim Shahwali and two bodyguards," Zwak told Reuters.
Three policemen and an Afghan soldier were wounded, Zwak said.
The attack came a day after three British soldiers were killed in a roadside bomb attack in Helmand.
In 2011, a suicide bomber disguised as a peace envoy killed the then chairman of the peace council, former president Burhanuddin Rabbani.
In May last year, gunmen in Kabul assassinated Arsala Rahmani, a former Taliban minister turned peace negotiator.
Helmand, which is the largest producer of opium in Afghanistan, has been the scene of the some of the fiercest fighting between NATO-led foreign forces and their Afghan government allies and the Taliban.
Fear is mounting that Afghanistan could be engulfed in turmoil after the pullout of most NATO combat troops by the end of 2014. A presidential election is also due that year.
NATO and its partners are training Afghanistan's 350,000-strong security forces, though questions remain over how well the Afghans will be able to tackle the insurgency.
Last week, the Taliban vowed to start a new campaign of suicide attacks on foreign military bases, diplomatic areas as well as the "Karzai regime" as part of their spring offensive.
(Reporting by Mohammad Sarwar; Writing by Hamid Shalizi; Editing by Robert Birsel)
Source: http://news.yahoo.com/taliban-kill-senior-peace-envoy-south-afghanistan-101446429.html
jennifer hudson tribute to whitney houston nicki minaj grammy jason whitlock beach boys tony bennett joe walsh the civil wars
Tuesday, April 30, 2013
Foul-smelling gas shows health benefits in reducing joint swelling
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 29-Apr-2013[ | E-mail |
Share ] Contact: Louise Vennells
l.vennells@exeter.ac.uk
44-013-927-24927
University of Exeter
A gas associated with the smell of rotten eggs has proven to effectively reduce joint swelling, in research which could lead to advances in the treatment of arthritis.
Scientists at the University of Exeter Medical School have discovered that a novel drug molecule, which slowly generates the gas hydrogen sulfide (H2S), effectively reduces swelling and inflammation in arthritic joints.
For years, H2S has been regarded as a highly poisonous by-product which is corrosive, flammable and explosive. But research is now showing an altogether more benign side to the substance.
Professor Matt Whiteman, of the University of Exeter Medical School, said the research, which is published online in the Journal of Cellular and Molecular Medicine, could pave the way for more effective treatments of arthritis and other inflammatory conditions. Prof Whiteman said: "H2S is widely dismissed as a toxic and foul-smelling environmental pollutant, but it has recently been shown to be created in humans and animals by a specific set of enzymes. Why would the body do this if it had no benefit? Our research has shown that the key to unlocking the therapeutic qualities of H2S is through slow release, mimicking the body's own production."
The team has previously shown that H2S levels were increased by up to four times in the knee joints of patients with joint diseases such as rheumatoid arthritis, but intriguingly the higher H2S levels strongly correlated with a lower number of inflammatory cells in the joint. The latest study provides further evidence that the real role for H2S may be to combat inflammation, swelling and joint destruction.
Prof Whiteman added: "A patient will usually visit their doctor with a joint already inflamed, swollen and painful. Since the compound worked after arthritis was established, it may be useful in treating arthritis in the future. Many compounds can prevent arthritis in the laboratory, but of course nobody knows when they will get arthritis. Having a class of compounds which reduce inflammation and swelling when arthritis is already active is extremely exciting. These molecules may also be useful in other inflammatory conditions, and even in the inflammatory aspects of diabetes and obesity."
The study was part of a large collaboration funded by the Wellcome Trust and Arthritis Research UK, involving Professor Philip K Moore and Dr Julie Keeble from King's College London, as well as researchers at the National University of Singapore and Queen's University, Belfast. The team used primary human cells as well as a model of arthritis. Rheumatoid arthritis causes some cells to proliferate too quickly in the joint and secrete substances which promote tissue inflammation, swelling and eventually joint destruction. However, the H2S donor molecule prevented this secretion, and inhibited the activity of several enzymes which cause inflation. In the arthritis model, the compound did not prevent arthritis, but was highly effective at reducing joint inflammation and swelling once arthritis was established, suggesting H2S-based compounds may one day be useful in clinic.
The same team has previously found that people who are overweight or have diabetes have lower levels of H2S in their bodies than healthy adults resulting in higher blood pressure, poorer insulin sensitivity and higher levels of sugar in their blood. It has also been reported to promote ulcer healing and reduce lung injury in smokers.
Co-author Dr Mark E Wood, at the University of Exeter, added: "Despite its reputation for being hazardous, H2S could in fact hold the key to solving some of the widespread health problems affecting the country. Our work is a major step in proving that it can be more hero than villain to the human body, providing it is administered in the right way, at the right time. We currently have several more efficient H2S donor molecules being evaluated with collaborators and this is a very exciting time for us."
Dr Julie Keeble, co-author from King's College London, commented: "The finding that H2S is able to reduce joint inflammation in experimental models makes it a very exciting prospect for treating arthritis. Many patients with arthritis do not respond effectively to current treatments or suffer side-effects from their medication. We hope that H2S-releasing drugs like the one tested in this study will be effective in treating arthritis without uncomfortable side effects."
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 29-Apr-2013[ | E-mail |
Share ] Contact: Louise Vennells
l.vennells@exeter.ac.uk
44-013-927-24927
University of Exeter
A gas associated with the smell of rotten eggs has proven to effectively reduce joint swelling, in research which could lead to advances in the treatment of arthritis.
Scientists at the University of Exeter Medical School have discovered that a novel drug molecule, which slowly generates the gas hydrogen sulfide (H2S), effectively reduces swelling and inflammation in arthritic joints.
For years, H2S has been regarded as a highly poisonous by-product which is corrosive, flammable and explosive. But research is now showing an altogether more benign side to the substance.
Professor Matt Whiteman, of the University of Exeter Medical School, said the research, which is published online in the Journal of Cellular and Molecular Medicine, could pave the way for more effective treatments of arthritis and other inflammatory conditions. Prof Whiteman said: "H2S is widely dismissed as a toxic and foul-smelling environmental pollutant, but it has recently been shown to be created in humans and animals by a specific set of enzymes. Why would the body do this if it had no benefit? Our research has shown that the key to unlocking the therapeutic qualities of H2S is through slow release, mimicking the body's own production."
The team has previously shown that H2S levels were increased by up to four times in the knee joints of patients with joint diseases such as rheumatoid arthritis, but intriguingly the higher H2S levels strongly correlated with a lower number of inflammatory cells in the joint. The latest study provides further evidence that the real role for H2S may be to combat inflammation, swelling and joint destruction.
Prof Whiteman added: "A patient will usually visit their doctor with a joint already inflamed, swollen and painful. Since the compound worked after arthritis was established, it may be useful in treating arthritis in the future. Many compounds can prevent arthritis in the laboratory, but of course nobody knows when they will get arthritis. Having a class of compounds which reduce inflammation and swelling when arthritis is already active is extremely exciting. These molecules may also be useful in other inflammatory conditions, and even in the inflammatory aspects of diabetes and obesity."
The study was part of a large collaboration funded by the Wellcome Trust and Arthritis Research UK, involving Professor Philip K Moore and Dr Julie Keeble from King's College London, as well as researchers at the National University of Singapore and Queen's University, Belfast. The team used primary human cells as well as a model of arthritis. Rheumatoid arthritis causes some cells to proliferate too quickly in the joint and secrete substances which promote tissue inflammation, swelling and eventually joint destruction. However, the H2S donor molecule prevented this secretion, and inhibited the activity of several enzymes which cause inflation. In the arthritis model, the compound did not prevent arthritis, but was highly effective at reducing joint inflammation and swelling once arthritis was established, suggesting H2S-based compounds may one day be useful in clinic.
The same team has previously found that people who are overweight or have diabetes have lower levels of H2S in their bodies than healthy adults resulting in higher blood pressure, poorer insulin sensitivity and higher levels of sugar in their blood. It has also been reported to promote ulcer healing and reduce lung injury in smokers.
Co-author Dr Mark E Wood, at the University of Exeter, added: "Despite its reputation for being hazardous, H2S could in fact hold the key to solving some of the widespread health problems affecting the country. Our work is a major step in proving that it can be more hero than villain to the human body, providing it is administered in the right way, at the right time. We currently have several more efficient H2S donor molecules being evaluated with collaborators and this is a very exciting time for us."
Dr Julie Keeble, co-author from King's College London, commented: "The finding that H2S is able to reduce joint inflammation in experimental models makes it a very exciting prospect for treating arthritis. Many patients with arthritis do not respond effectively to current treatments or suffer side-effects from their medication. We hope that H2S-releasing drugs like the one tested in this study will be effective in treating arthritis without uncomfortable side effects."
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-04/uoe-fgs042913.php
Kamala Harris URI Facebook Home Ncaa Basketball Tournament 2013 Robert Ebert blake shelton chelsea handler
SAY WHAT?! A Texas woman was arrested after she allegedly entered a home through...
SAY WHAT?! A Texas woman was arrested after she allegedly entered a home through a doggy door, got naked, then was found sitting in a dry bathtub with the curtain drawn. She told officers that she was trying to get to California because she was signed to a rap label. She then rapped a song to officers on her way to jail. It was about smoking pot.
http://www.nbc33tv.com/news/woman-arrested-for-trespa
Source: http://www.facebook.com/wvlanbc33/posts/599830453361125
nflx chicago blackhawks giuliana rancic giuliana rancic elie wiesel temptations work hard play hard
Surgery for nonfatal skin cancers might not be best for elderly patients
Public release date: 29-Apr-2013[ | E-mail |
Share ] Contact: Elizabeth Fernandez
elizabeth.fernandez@ucsf.edu
415-502-6397
University of California - San Francisco
New UCSF study urges doctors to consider patient risks and benefits when treating benign skin cancers
Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment.
A new study led by UC San Francisco focused on the vexing problem of how best to handle skin cancers among frail, elderly patients. In the study sample, the researchers found that most non-melanoma skin cancers were typically treated surgically, regardless of the patient's life expectancy or whether the tumor was likely to recur or harm the patient.
One in five patients in the study reported a complication from the skin cancer treatment, and approximately half the patients with limited life expectancy died of other causes within five years.
As a result, the authors say, doctors should take into consideration the benefits, risk and preference of a patient when determining appropriate treatment for nonfatal skin cancers.
The study will be published online on April 29, 2013 in JAMA Internal Medicine.
"It can be very challenging to decide whether and how to treat patients with non-melanoma skin cancer who have limited life expectancy, especially when the tumors are asymptomatic," said Eleni Linos, MD, DrPH, an assistant professor of dermatology at UCSF and lead author of the study.
"One challenge is that it is hard to precisely predict an individual's life expectancy," Linos noted. "Another challenge is that elderly patients are very diverse. For example, some 90-year-olds are active, healthy and would like to choose the most aggressive treatments for skin cancer, while others are very frail and unable to care for themselves, and may prefer less invasive management for a skin cancer that doesn't bother them.
"Bothersome or medically dangerous skin tumors should always be treated, regardless of age or life expectancy," Linos said. "But treatment of asymptomatic tumors might not be the best option for all patients."
Skin cancers are by far the most common type of cancer, according to the American Cancer Society. An estimated 2.2 million Americans predominantly older patients are diagnosed annually with a non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma. This type of cancer can be slow-growing and typically does not affect survival or short-term quality of life.
"The current standard of care in the United States is to treat non-melanoma skin cancers," the authors wrote in their study, "and no guidelines exist about whether physicians should consider patient age or functional status in choosing treatments."
In comparing treatment options and clinical options, the researchers followed more than 1,300 patients in San Francisco for about a decade. About a quarter of the patients were classified as having limited life expectancy because they were at least 85 years old or they suffered from multiple serious health conditions.
Most of the non-melanoma skin cancers were treated surgically, a taxing process for seniors who have difficulty tolerating extended procedures or adequately treating their wounds at home. The researchers found that medical complications included poor wound healing, numbness, itching and pain.
Tumor recurrence was very low less than 4 percent after five years, the authors said. Nearly half the patients with limited life expectancy died within five years none of the deaths resulted from the skin cancers, the researchers reported. Most deaths were related to heart disease, cerebrovascular disease, lung cancer, pneumonia, chronic respiratory disease, prostate cancer and Alzheimer's disease.
"The findings highlight a challenge not just for dermatologists, but for all physicians treating non-fatal conditions," said senior author Mary-Margaret Chren, MD, a dermatology professor at the UCSF School of Medicine. "Our study provides useful evidence for clinicians facing a treatment choice dilemma with their patients it focuses on a cancer whose natural history is generally benign, where treatment itself may be discretionary."
###
The research was conducted by the unit for patient-oriented research in skin disease at UCSF, and supported by the National Center for Research Resources (Award KL2RR024130); the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (Grants R01 AR 054983 and K24 AR052667); and by a Career Development Award from the American Skin Association and Dermatology Foundation.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
Follow UCSF
UCSF.edu | Facebook.com/ucsf | Twitter.com/ucsf | YouTube.com/ucsf
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 29-Apr-2013[ | E-mail |
Share ] Contact: Elizabeth Fernandez
elizabeth.fernandez@ucsf.edu
415-502-6397
University of California - San Francisco
New UCSF study urges doctors to consider patient risks and benefits when treating benign skin cancers
Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment.
A new study led by UC San Francisco focused on the vexing problem of how best to handle skin cancers among frail, elderly patients. In the study sample, the researchers found that most non-melanoma skin cancers were typically treated surgically, regardless of the patient's life expectancy or whether the tumor was likely to recur or harm the patient.
One in five patients in the study reported a complication from the skin cancer treatment, and approximately half the patients with limited life expectancy died of other causes within five years.
As a result, the authors say, doctors should take into consideration the benefits, risk and preference of a patient when determining appropriate treatment for nonfatal skin cancers.
The study will be published online on April 29, 2013 in JAMA Internal Medicine.
"It can be very challenging to decide whether and how to treat patients with non-melanoma skin cancer who have limited life expectancy, especially when the tumors are asymptomatic," said Eleni Linos, MD, DrPH, an assistant professor of dermatology at UCSF and lead author of the study.
"One challenge is that it is hard to precisely predict an individual's life expectancy," Linos noted. "Another challenge is that elderly patients are very diverse. For example, some 90-year-olds are active, healthy and would like to choose the most aggressive treatments for skin cancer, while others are very frail and unable to care for themselves, and may prefer less invasive management for a skin cancer that doesn't bother them.
"Bothersome or medically dangerous skin tumors should always be treated, regardless of age or life expectancy," Linos said. "But treatment of asymptomatic tumors might not be the best option for all patients."
Skin cancers are by far the most common type of cancer, according to the American Cancer Society. An estimated 2.2 million Americans predominantly older patients are diagnosed annually with a non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma. This type of cancer can be slow-growing and typically does not affect survival or short-term quality of life.
"The current standard of care in the United States is to treat non-melanoma skin cancers," the authors wrote in their study, "and no guidelines exist about whether physicians should consider patient age or functional status in choosing treatments."
In comparing treatment options and clinical options, the researchers followed more than 1,300 patients in San Francisco for about a decade. About a quarter of the patients were classified as having limited life expectancy because they were at least 85 years old or they suffered from multiple serious health conditions.
Most of the non-melanoma skin cancers were treated surgically, a taxing process for seniors who have difficulty tolerating extended procedures or adequately treating their wounds at home. The researchers found that medical complications included poor wound healing, numbness, itching and pain.
Tumor recurrence was very low less than 4 percent after five years, the authors said. Nearly half the patients with limited life expectancy died within five years none of the deaths resulted from the skin cancers, the researchers reported. Most deaths were related to heart disease, cerebrovascular disease, lung cancer, pneumonia, chronic respiratory disease, prostate cancer and Alzheimer's disease.
"The findings highlight a challenge not just for dermatologists, but for all physicians treating non-fatal conditions," said senior author Mary-Margaret Chren, MD, a dermatology professor at the UCSF School of Medicine. "Our study provides useful evidence for clinicians facing a treatment choice dilemma with their patients it focuses on a cancer whose natural history is generally benign, where treatment itself may be discretionary."
###
The research was conducted by the unit for patient-oriented research in skin disease at UCSF, and supported by the National Center for Research Resources (Award KL2RR024130); the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (Grants R01 AR 054983 and K24 AR052667); and by a Career Development Award from the American Skin Association and Dermatology Foundation.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
Follow UCSF
UCSF.edu | Facebook.com/ucsf | Twitter.com/ucsf | YouTube.com/ucsf
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-04/uoc--sfn042913.php
March Madness Live Google Keep ncaa scores Splash Ncaa Basketball Tournament NCAA Bracket 2013 Robert Morris
Subscribe to:
Posts (Atom)